PROCEPT BioRobotics Corp (PRCT): Price and Financial Metrics
PRCT Price/Volume Stats
| Current price | $33.54 | 52-week high | $52.40 |
| Prev. close | $31.53 | 52-week low | $25.29 |
| Day low | $31.37 | Volume | 403,100 |
| Day high | $33.58 | Avg. volume | 370,084 |
| 50-day MA | $32.00 | Dividend yield | N/A |
| 200-day MA | $38.12 | Market Cap | 1.51B |
PRCT Stock Price Chart Interactive Chart >
PRCT POWR Grades
- Sentiment is the dimension where PRCT ranks best; there it ranks ahead of 27.12% of US stocks.
- The strongest trend for PRCT is in Growth, which has been heading down over the past 179 days.
- PRCT ranks lowest in Quality; there it ranks in the 3rd percentile.
PRCT Stock Summary
- PRCT's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than merely 5.47% of US-listed equities with positive expected earnings growth.
- PROCEPT BIOROBOTICS CORP's stock had its IPO on September 15, 2021, making it an older stock than merely 3.4% of US equities in our set.
- With a price/sales ratio of 17.16, PROCEPT BIOROBOTICS CORP has a higher such ratio than 93.57% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to PROCEPT BIOROBOTICS CORP are LVOX, RNLX, STRM, OSS, and SSYS.
- To check out PROCEPT BIOROBOTICS CORP's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001588978.
PRCT Valuation Summary
- PRCT's price/sales ratio is 17.4; this is 241.18% higher than that of the median Healthcare stock.
- Over the past 20 months, PRCT's EV/EBIT ratio has gone up 18.7.
Below are key valuation metrics over time for PRCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PRCT | 2023-05-23 | 17.4 | 8.6 | -15.1 | -14.7 |
| PRCT | 2023-05-22 | 17.7 | 8.7 | -15.3 | -15.0 |
| PRCT | 2023-05-19 | 17.1 | 8.4 | -14.8 | -14.4 |
| PRCT | 2023-05-18 | 17.4 | 8.5 | -15.0 | -14.7 |
| PRCT | 2023-05-17 | 17.2 | 8.5 | -14.9 | -14.5 |
| PRCT | 2023-05-16 | 17.6 | 8.7 | -15.2 | -14.9 |
PROCEPT BioRobotics Corp (PRCT) Company Bio
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is based in Redwood City, California.
Latest PRCT News From Around the Web
Below are the latest news stories about PROCEPT BIOROBOTICS CORP that investors may wish to consider to help them evaluate PRCT as an investment opportunity.
Positive week for PROCEPT BioRobotics Corporation (NASDAQ:PRCT) institutional investors who lost 17% over the past yearKey Insights Significantly high institutional ownership implies PROCEPT BioRobotics' stock price is sensitive to their... |
7 Growth Stocks That Could Double Your Money in 2023For investors that really want to roll the dice, these are the enticing growth stocks that could double your money. |
Five-Year Data from the WATER II Study Demonstrate Aquablation Therapy Delivers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms while Preserving Sexual Function in Men with Large Prostates5-Year results from WATER II when combined with 5-year results from the original WATER study demonstrate that Aquablation therapy provides long-term symptom relief while preserving sexual function for patients with small and large prostates.The study concluded that Aquablation therapy: Is safe, effective and durable with symptoms metrics demonstrating large immediate and sustained improvements for patients96.3% of patients based on Kaplan-Meier analysis avoided a secondary intervention due to re |
Why Shares of Procept Biorobotics Were Slumping ThursdayShares of Procept Biorobotics (NASDAQ: PRCT) were down more than 21% as of 12:48 p.m. ET Thursday after the healthcare company released first-quarter earnings before the trading day opened. Procept makes the AquaBeam Robotic System, which is designed to be used in performing minimally invasive urology surgeries. At Procept's current burn rate, that would only fund operations into early 2024. |
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue EstimatesPROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -6.78% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
PRCT Price Returns
| 1-mo | 17.52% |
| 3-mo | -1.79% |
| 6-mo | -22.56% |
| 1-year | -16.32% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -19.26% |
| 2022 | 66.09% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...